Definium Therapeutics, Inc.

DFTXSEC EDGAR

Medicinal Chemicals & Botanical Products(A1)CIK: 1813814

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$65.3M	$52.1M	$36.2M	$34.8M	$7.5M
Operating Expenses	$103.9M	$93.9M	$66.3M	$93.9M	$10.7M
Operating Income (Loss)	-$103.9M	-$93.9M	-$66.3M	-$93.9M	-$10.7M
Interest Expense	$2.3M	$920.0K	—	—	—
Other Nonoperating Income (Expense)	-$4.8M	-$1.9M	$9.5M	-$339.0K	$28.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$108.7M	-$95.7M	-$56.8M	-$94.2M	-$10.7M
Income Tax Expense (Benefit)	$0.00	—	—	-$1.2M	-$1.2M
Net Income (Loss) Attributable to Parent	-$108.7M	-$95.7M	-$56.8M	-$93.0M	-$10.7M
Earnings Per Share, Basic	-$1.54	-$2.44	-$1.84	-$3.40	—
Earnings Per Share, Diluted	-$1.54	-$2.44	-$1.84	-$3.40	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$302.2M	$124.5M	$170.0M	$164.0M	$81.5M
Assets, Current	$281.6M	$103.9M	$146.1M	$137.2M	$81.5M
Cash and Cash Equivalents, at Carrying Value	$273.7M	$99.7M	$142.1M	$133.5M	$80.1M
Liabilities	$60.7M	$46.4M	$19.1M	$12.3M	$5.7M
Liabilities, Current	$38.8M	$32.2M	$17.9M	$10.4M	$3.0M
Long-term Debt, Excluding Current Maturities	$40.6M	$21.9M	$14.1M	—	—
Accounts Payable, Current	$2.0M	$4.1M	$2.1M	$4.2M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$79.1M	-$64.4M	-$50.1M	-$45.8M	-$3.2M
Net Cash Provided by (Used in) Investing Activities	$0.00	—	—	-$297.0K	-$297.0K
Net Cash Provided by (Used in) Financing Activities	$253.2M	$21.8M	$59.1M	$98.8M	$9.9M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)